These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33050728)

  • 1. Comparison Between Closed-Loop Insulin Delivery System (the Artificial Pancreas) and Sensor-Augmented Pump Therapy: A Randomized-Controlled Crossover Trial.
    Haidar A; Legault L; Raffray M; Gouchie-Provencher N; Jacobs PG; El-Fathi A; Rutkowski J; Messier V; Rabasa-Lhoret R
    Diabetes Technol Ther; 2021 Mar; 23(3):168-174. PubMed ID: 33050728
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial.
    McAuley SA; Trawley S; Vogrin S; Ward GM; Fourlanos S; Grills CA; Lee MH; Alipoor AM; O'Neal DN; O'Regan NA; Sundararajan V; Colman PG; MacIsaac RJ
    Diabetes Care; 2022 Feb; 45(2):381-390. PubMed ID: 34844995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.
    Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 May; 19(5):713-720. PubMed ID: 28094472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies.
    Hovorka R; Kumareswaran K; Harris J; Allen JM; Elleri D; Xing D; Kollman C; Nodale M; Murphy HR; Dunger DB; Amiel SA; Heller SR; Wilinska ME; Evans ML
    BMJ; 2011 Apr; 342():d1855. PubMed ID: 21493665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
    Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
    CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
    Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
    BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home.
    Biester T; Nir J; Remus K; Farfel A; Muller I; Biester S; Atlas E; Dovc K; Bratina N; Kordonouri O; Battelino T; Philip M; Danne T; Nimri R
    Diabetes Obes Metab; 2019 Apr; 21(4):822-828. PubMed ID: 30478937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Day-and-Night Hybrid Closed-Loop Insulin Delivery in Adolescents With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial.
    Tauschmann M; Allen JM; Wilinska ME; Thabit H; Stewart Z; Cheng P; Kollman C; Acerini CL; Dunger DB; Hovorka R
    Diabetes Care; 2016 Jul; 39(7):1168-74. PubMed ID: 26740634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the efficacy, safety and utility of 6-month day-and-night automated closed-loop insulin delivery under free-living conditions compared with insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, multicentre, multinational, single-period, randomised, parallel group study protocol.
    Musolino G; Allen JM; Hartnell S; Wilinska ME; Tauschmann M; Boughton C; Campbell F; Denvir L; Trevelyan N; Wadwa P; DiMeglio L; Buckingham BA; Weinzimer S; Acerini CL; Hood K; Fox S; Kollman C; Sibayan J; Borgman S; Cheng P; Hovorka R
    BMJ Open; 2019 Jun; 9(6):e027856. PubMed ID: 31164368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes.
    Thabit H; Elleri D; Leelarathna L; Allen JM; Lubina-Solomon A; Stadler M; Walkinshaw E; Iqbal A; Choudhary P; Wilinska ME; Barnard KD; Heller SR; Amiel SA; Evans ML; Dunger DB; Hovorka R
    Diabetes Obes Metab; 2015 May; 17(5):452-8. PubMed ID: 25492378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
    El-Khatib FH; Balliro C; Hillard MA; Magyar KL; Ekhlaspour L; Sinha M; Mondesir D; Esmaeili A; Hartigan C; Thompson MJ; Malkani S; Lock JP; Harlan DM; Clinton P; Frank E; Wilson DM; DeSalvo D; Norlander L; Ly T; Buckingham BA; Diner J; Dezube M; Young LA; Goley A; Kirkman MS; Buse JB; Zheng H; Selagamsetty RR; Damiano ER; Russell SJ
    Lancet; 2017 Jan; 389(10067):369-380. PubMed ID: 28007348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
    Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
    Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.
    Bally L; Thabit H; Kojzar H; Mader JK; Qerimi-Hyseni J; Hartnell S; Tauschmann M; Allen JM; Wilinska ME; Pieber TR; Evans ML; Hovorka R
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):261-270. PubMed ID: 28094136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.
    Russell SJ; Hillard MA; Balliro C; Magyar KL; Selagamsetty R; Sinha M; Grennan K; Mondesir D; Ekhlaspour L; Zheng H; Damiano ER; El-Khatib FH
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):233-243. PubMed ID: 26850709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial.
    Kim JY; Jin SM; Kang ES; Kwak SH; Yang Y; Yoo JH; Bae JH; Moon JS; Jung CH; Bae JC; Suh S; Moon SJ; Song SO; Chon S; Kim JH
    Diabetologia; 2024 Jul; 67(7):1235-1244. PubMed ID: 38634887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes.
    Stewart ZA; Wilinska ME; Hartnell S; Temple RC; Rayman G; Stanley KP; Simmons D; Law GR; Scott EM; Hovorka R; Murphy HR
    N Engl J Med; 2016 Aug; 375(7):644-54. PubMed ID: 27532830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study.
    Leelarathna L; Dellweg S; Mader JK; Allen JM; Benesch C; Doll W; Ellmerer M; Hartnell S; Heinemann L; Kojzar H; Michalewski L; Nodale M; Thabit H; Wilinska ME; Pieber TR; Arnolds S; Evans ML; Hovorka R;
    Diabetes Care; 2014 Jul; 37(7):1931-7. PubMed ID: 24963110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial.
    Tauschmann M; Allen JM; Wilinska ME; Thabit H; Acerini CL; Dunger DB; Hovorka R
    Diabetes Care; 2016 Nov; 39(11):2019-2025. PubMed ID: 27612500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes.
    Ware J; Allen JM; Boughton CK; Wilinska ME; Hartnell S; Thankamony A; de Beaufort C; Schierloh U; Fröhlich-Reiterer E; Mader JK; Kapellen TM; Rami-Merhar B; Tauschmann M; Nagl K; Hofer SE; Campbell FM; Yong J; Hood KK; Lawton J; Roze S; Sibayan J; Bocchino LE; Kollman C; Hovorka R;
    N Engl J Med; 2022 Jan; 386(3):209-219. PubMed ID: 35045227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.